* Bio-Technology General Corp., of Iselin, N.J., said its humangrowth hormone, Bio-Tropin, received marketing approval inArgentina for the treatment of growth hormone-deficient children.

* Celgene Corp., of Warren, N.J., said the FDA approved its secondapplication for orphan drug designation of thalidomide, for treatmentof recurrent canker sores in terminally immunocompromised patients.

* Curative Technologies Inc., of East Setauket, N.Y., said it fullydivested its majority ownership in Curative Technologies GmbH, ofGermany.

* Medco Research Inc., of Research Triangle Park, N.C., said itslicensee has been granted clearance for Adenoscan (adenosineinjection) in the U.K.

(c) 1997 American Health Consultants. All rights reserved.